All In Biotech

Drug Trial Radar · NCT05745727

A Study to Evaluate the Safety, Tolerability, PK, and PD Properties of PRX-115 in Adult Volunteers With Elevated Uric Acid Levels

A Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Properties of PRX-115 in Adult Volunteers With Elevated Uric Acid Levels.

Last checked: Nov 19, 2026Latest source record: Feb 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

64

Actual

Start

Mar 23, 2023

Primary completion

Aug 26, 2024

Study completion Feb 6, 2025

Sponsor

Lead sponsor
ProtalixIndustry
Sponsor type
Industry
First posted
Feb 27, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1, double-blind, placebo-controlled, single ascending dose study in participants with elevated uric acid levels. This study will be conducted in approximately 64 adult male and female participants in the dose escalation phase.

Conditions

  • Gout

Interventions

  • PRX-115Drug

    Escalating doses of PRX-115 will be given in different cohorts i.e., Cohorts 1 through 8

  • PlaceboDrug

    Escalating doses of Placebo will be given in different cohorts i.e., Cohorts 1 through 8

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events receiving PRX-115 compared to placeboTime frame: Day 0 - Day 85
  2. Number of participants with abnormal clinically significant clinical laboratory resultsTime frame: Day 0 - Day 85
  3. Number of participants with abnormal clinical vital signsTime frame: Day 0 - Day 85
  4. Number of participants with abnormal clinically significant results from physical examinationTime frame: Day 0 - Day 85
  5. Number of participants with abnormal clinically significant 12-lead electrocardiogram (ECG) parametersTime frame: Day 0 - Day 85

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • New Zealand Clinical Research

    Grafton, Auckland, New Zealand

  • New Zealand Clinical Research

    Christchurch, Christchurch, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.